References

1. NIH stops clinical trial on combination cholesterol treatment. http://www.nih.gov/news/health/may2011/nhlbi-26.htm. Accessed 26 May 2011.

2. Chapman MJ, Ginsberg HN, Amarenco P, et al, European Atherosclerosis Society Consensus Panel. Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for management. Eur Heart J 2011;32: 1345-61, doi:10.1093/eurheartj/ehr112.

3. Gajos G, Zalewski J, Rostoff P, et al. Reduced thrombin formation and altered fibrin clot properties induced by polyunsaturated omega-3 fatty acids on top of dual antiplatelet therapy in patients undergoing percutaneous coronary intervention (OMEGA-PCI Clot). Arterioscler Thromb Vasc Biol 2011; DOI: 10.1161/ATVBAHA.111.228593. [Epub ahead of print]. 

4. Undas A, Stepién E, Branicka A, Wolkow P, Zmudka K, Tracz W. Thrombin formation and platelet activation at the site of vascular injury in patients with coronary artery disease treated with clopidogrel combined with aspirin. Kardiol Pol 2009;67:591-8.

5. Undas A, Celinska-Löwenhoff M, Löwenhoff T, Szczeklik A. Statins, fenofibrate, and quinapril increase clot permeability and enhance fibrinolysis in patients with coronary artery disease. J Thromb Haemost 2006;4:973-5.

6. Holy EW, Forestier M, Richter EK et al. Dietary -linolenic acid inhibits arterial thrombus formation, tissue factor expression, and platelet activation. Arterioscler Thromb Vasc Biol 2011;31:DOI 10.1161/ATVBAHA.111.226118. [Epub ahead of print].

7. de Lorgeril M, Renaud S, Mamelle N et al. Mediterranean -linolenic acid-rich diet in secondary prevention of coronary heart disease. Lancet 1994;343:1454-9.

8. Albert CM, Oh K, Whang M et al. Dietary linolenic acid intake and risk of sudden cardiac death and coronary heart disease. Circulation 2005;112:3232-8.

9. Adkim F, Tribble DL, Flaim JD et al. Efficacy of apolipoprotein B synthesis inhibition in subjects with mild-to-moderate hyperlipidemia. Eur Heart J 2011;doi:10.1093.eurheartj/ehr148 [Epub ahead of print].

10. Nordestgaard BG, Chapman MJ, Ray K et al. Lipoprotein(a) as a cardiovascular risk factor: current status. Eur Heart J 2010;31:2844-53.

11. Goldberg IJ, Eckel RH, McPherson R. Triglycerides and heart disease. Still a hypothesis? Arterioscler Thromb Vasc Biol 2011;31, doi 10.1161/ATVBAHA.111.226100 [Published on-line ahead of print].

12. Johansen C T, Wang J, Lanktree MB et al. An increased burden of common and rare lipid-associated risk alleles contributes to the phenotypic spectrum of hypertriglyceridemia. Arterisocler Thromb Vasc Biol 2011;31, doi: 10.1161/atvbaha.111.226365 [Epub ahead of print].

13. Hegele RA, Ban MR, Hsueh N et al. A polygenic basis for four classical Fredrickson hyperlipoproteinemia phenotyopes that are characterized by hypertriglyceridemia. Hum Mol Genet 2009;18:4189-94.

14. Teslovich TM, Musunuru K, Smith AV, et al. Biological, clinical and population relevance of 95 loci for blood lipids. Nature 2010;466:707-13.